findmyKOL
Clinical trialNCT00860015CompletedPhase 2Interventional

Alimta Plus Gemcitabine for Advanced Sarcoma

SponsorColumbia UniversityEnrollment12Sarcoma, Soft Tissue
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

In patients with unresectable soft tissue sarcoma, what is the response rate if treated with Alimta and gemcitabine?
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Columbia University Medical Center

    New York, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pemetrexed →Gemcitabine →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Aug 2005
Primary completion
31 Aug 2009
Completion
30 Apr 2012
Last update posted
25 Aug 2020
Registered enrollment
12
Registry id
NCT00860015
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.